1. Unal S, Cetin M, Tavil B, Caliskan N, Yetgin S, Uckan D. Favorable Outcome with Allogeneic
Total Page：16
File Type：pdf, Size：1020Kb
1. Unal S, Cetin M, Tavil B, Caliskan N, Yetgin S, Uckan D. Favorable outcome with allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia patients. Pediatr Transplant 2007;11(7):788-791. 2. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood [Epub ahead of print] 2007:Nov 7. 3. Dincol G, Aktan M, Diz-Kucukkaya R, Yavuz S, Nalcaci M, Ozturk S, et al. Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporin A, methyprednisolone, and granulocyte colony-stimulating factor. Am J Hematol 2007;82(9):783-6. 4. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 2006;34(7):826-31. 5. Leleu X, Terriou L, Duhamel A, Moreau A, Andrieux J, Dupire S, et al. Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. Ann Hematol 2006;85(10):711-6.
6. Seidel M, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Potschger U, et al. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica 2005;90(10):1405-14. 7. Chandy M, Balasubramanian P, Ramachandran S, Mathews V, George B, Dennison D, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005:839-45. 8. Iori A, Cerretti R, De Felice L, Screnci M, Mengarelli A, Romano A, et al. Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation. Bone Marrow Transplant 2004;33(11):1097-1105. 9. Yoshikawa T, Ihira M, Ohashi M, Suga S, Asano Y, Miyazaki H, et al. Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28(1):77-81. 10. Muller T, Ruffingshofer D, Bidmon B, Arbeiter K, Balzar E, Aufricht C. Reduction of delayed renal allograft function using sequential immunosuppression. Pediatr Nephrol 2001;16(8):613-617. 11. Gaziev D, Galimberti M, Lucarelli G, Polchi P, Giardini C, Angellucci E, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplant 2000;25(8):815-821. 12. Tung J, Hadzic N, Layton M, Baker A, Dhawan A, Rela M, et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr 2000;31(5):557-561. 13. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000;95(6):1931-1934. 14. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96(6):2049-2054. 15. Yagasaki H, Kojima S, Inaba J, Kato K, Matsuyama T. [Clinical trial of antithymocyte globulin for prophylaxis of acute graft-versus-host disease in pediatric recipients of bone marrow transplantation from unrelated donors] (in Japanese). Rinsho Ketsueki- Japanese Journal of Clinical Hematology 1999;40(5):382-9. 16. Marsh JCW, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999;93(7):2191-2195. 17. Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Wodnar F, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998;100(2):393-400. 18. Brun P, Sterkers G, Maisin A, Benali K, Baudouin V, Macher M, et al. Flow-cytometry monitoring of antilymphocyte globulin therapy in pediatric renal transplantation. Transplantation proceedings 1995;27:1744-1745. 19. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony- stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995;85:1348-1353. 20. Higashigawa M, Watanabe M, Nishihara H, Tabata N, Azuma E, Ido M, et al. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin e-1. Leuk Res 1995;19:477- 480. 21. Polchi P, Lucarelli G, Galimberti M, Giardini C, Baronciani D, Angellucci E, et al. Haploidentical bone marrow transplantation from mother to child with advanced leukemia. Bone Marrow Transplant 1995;16:529-535. 22. Mordacchini M, Galconi G, Di Falco G, Innocenti P, Maresca M, Mastrosimone S, et al. CD3+ and CD19+ lymphocyte depletion following a course of anti- lymphocyte globulin in renal allograft recipients. Clin Transplant 1992;6:69-72. 23. Hesse U, Wienand P, Baldamus C, Pollok M, Pichlmaier H. The risk of infection following OKT3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial. Transplant Int. 1992;5 (SUPPL 1):S440-S443. 24. Gulanikar A, MacDonald A, Sungurtekin U, Belitsky P. The Incidence and Impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992;53(2):323-328. 25. Grino J, Castelao A, Seron D, Gonzalez C, Galceran J, Gil-Vernet S, et al. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Am J Kidney Dis 1992;20(6):603-10. 26. Gluckman E, Esperou-Bourdeau H, Baruchel A, Boogaerts M, Briere J, Donadio D, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 1992;79(10):2540-2546. 27. Au J, Gregory J, Colquhoun I, Scott C, Hilton C, Hunter S, et al. Paediatric cardiac transplantation with steroid-sparing maintenance immunosuppression. Archives of disease in childhood 1992;67:1262-1266. 28. Frickhofen N, Kaltwasser J. Immunosuppressive treatment of aplastic anemia: a prospective randomized multicenter trial evaluating antilymphocyte globulin (ALG) versus ALG and cyclosporin A. Blut 1988;56:191-192. 29. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 1988;68:139-140. 30. Broyer M, Gagnadoux M, Guest G, Niaudet P. Triple therapy including cyclosporine A versus conventional regimen--a randomized prospective study in pediatric kidney transplantation. Transplantation proceedings 1987;19:3582-3585. 31. Marsh J, Hows J, Bryett K, Al Hashimi S, Fairhead S, Gordon Smith E. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987;70:1046-1052. 32. Gratama J, Brand A, Jansen J, Zwaan F, Valentijn R, Eernisse J. Factors influencing platelet survival during antilymphocyte globulin treatment. Br J Haematol 1984;57:5-15. 33. Fairhead S, Chipping P, Gordon Smith E. Treatment of aplastic anaemia with antilymphocyte globulin (ALG). Br J Haematol 1983;55:7-16. 34. Gluckman E, Devergie A, Faille A, Barrett A, Bonneau M, Boiron M, et al. Treatment of severe aplastic anemia with antilymphocyte globulin and androgens. Exp Hematol 1978;6:679-687.